RxDoctor Payments Data

Christopher Kim, MD

Interventional Pain Medicine · Charleston, WVNPI 1780619742

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Abbott at 43.1% of the total. Reporting peaked in 2020 at $28,305 and has fallen 81.7% since, to $5,184 in 2025.

$107,596in general payments, 2019–2025

Across 507 payments — averaging $212.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$46K
  • Boston Scientific$25K
  • Vertos Medical, Inc.$15K
  • Vertiflex, Inc.$12K
  • Aurora Spine, Inc.$4K
  • Spinal Simplicity, LLC$3K
  • plus $3K from 12 others
$170,264in research payments, 2019–2025

Across 169 payments — averaging $1007.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertos Medical, Inc.$109K
  • Saluda Medical Americas, Inc.$29K
  • Painteq LLC$14K
  • Stryker$10K
  • Abbott$9K

What the payments were for

  • Consulting fees$55,49952%
  • Speaking & faculty fees$30,50028%
  • Travel & lodging$5401%
  • Food & beverage$21,05720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$256,025
Medicare patients
462
Services billed
1,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fentanyl127$13,647
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen807$12,626
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen531$11,398
Buprenorphine28$9,497
Oxycodone Hcl192$3,304
Methadone Hcl134$2,333
Morphine Sulfate ErMorphine Sulfate90$1,998
Gabapentin168$1,685
Acetaminophen-CodeineAcetaminophen With Codeine49$1,440
Tramadol Hcl159$1,005
Tizanidine Hcl110$810
Lidocaine11$804
Cephalexin116$541
Etodolac11$471
Nabumetone31$418

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →